What are the reasons for negative phase III trials of molecular-target-based drugs?

Abstract

The results of molecular-biological studies of cancer are changing the way we diagnose and treat cancer. Target-based drug discovery selects agents for development based on their mechanisms of action. The interaction between target-based drugs and their targets can be described by classical drug-receptor theory. Clinical trials have demonstrated that some… (More)

Topics

Cite this paper

@article{Saijo2004WhatAT, title={What are the reasons for negative phase III trials of molecular-target-based drugs?}, author={Nagahiro George Saijo}, journal={Cancer science}, year={2004}, volume={95 10}, pages={772-6} }